Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gamma Delta Hepatosplenic T-Cell Lymphoma”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)UnknownNCT01719835
What this trial is testing

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Who this might be right for
Peripheral T-cell Lymphoma NOSAnaplastic Large Cell Lymphoma, ALK-NegativeAngioimmunoblastic T-cell Lymphoma+2 more
Royal Marsden NHS Foundation Trust 87
Testing effectiveness (Phase 2)Looking for participantsNCT05475925
What this trial is testing

DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Who this might be right for
LGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell LymphomaPrimary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma+10 more
Dren Bio 200
Early research (Phase 1)Ended earlyNCT00671112
What this trial is testing

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Who this might be right for
714leukemiaLymphoma
Brian Hill, MD, PhD 30
Early research (Phase 1)Active Not RecruitingNCT05377827
What this trial is testing

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Who this might be right for
T-Cell Non-Hodgkin LymphomaAcute Myeloid LeukemiaAngioimmunoblastic T-cell Lymphoma+12 more
Washington University School of Medicine 6
Testing effectiveness (Phase 2)Ended earlyNCT00810576
What this trial is testing

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 1
Early research (Phase 1)Study completedNCT01445535
What this trial is testing

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Who this might be right for
T-Cell Peripheral LymphomaGamma Delta Hepatosplenic T-Cell LymphomaSubcutaneous Panniculitis-Like T-Cell Lymphoma+1 more
National Cancer Institute (NCI) 15